These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21714003)

  • 1. Kin-cohort analysis of LRRK2-G2019S penetrance in Parkinson's disease.
    Goldwurm S; Tunesi S; Tesei S; Zini M; Sironi F; Primignani P; Magnani C; Pezzoli G
    Mov Disord; 2011 Sep; 26(11):2144-5. PubMed ID: 21714003
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson disease.
    Goldwurm S; Zini M; Mariani L; Tesei S; Miceli R; Sironi F; Clementi M; Bonifati V; Pezzoli G
    Neurology; 2007 Apr; 68(14):1141-3. PubMed ID: 17215492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation.
    Kay DM; Kramer P; Higgins D; Zabetian CP; Payami H
    Mov Disord; 2005 Aug; 20(8):1077-8. PubMed ID: 16001413
    [No Abstract]   [Full Text] [Related]  

  • 4. G2019S dardarin substitution is a common cause of Parkinson's disease in a Portuguese cohort.
    Bras JM; Guerreiro RJ; Ribeiro MH; Januario C; Morgadinho A; Oliveira CR; Cunha L; Hardy J; Singleton A
    Mov Disord; 2005 Dec; 20(12):1653-5. PubMed ID: 16149095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry.
    Lee AJ; Wang Y; Alcalay RN; Mejia-Santana H; Saunders-Pullman R; Bressman S; Corvol JC; Brice A; Lesage S; Mangone G; Tolosa E; Pont-Sunyer C; Vilas D; Schüle B; Kausar F; Foroud T; Berg D; Brockmann K; Goldwurm S; Siri C; Asselta R; Ruiz-Martinez J; Mondragón E; Marras C; Ghate T; Giladi N; Mirelman A; Marder K;
    Mov Disord; 2017 Oct; 32(10):1432-1438. PubMed ID: 28639421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study.
    Mestre TA; Pont-Sunyer C; Kausar F; Visanji NP; Ghate T; Connolly BS; Gasca-Salas C; Kern DS; Jain J; Slow EJ; Faust-Socher A; Kasten M; Wadia PM; Zadikoff C; Kumar P; de Bie RM; Thomsen T; Lang AE; Schüle B; Klein C; Tolosa E; Marras C
    Mov Disord; 2018 Jul; 33(6):960-965. PubMed ID: 29665080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study.
    Latourelle JC; Sun M; Lew MF; Suchowersky O; Klein C; Golbe LI; Mark MH; Growdon JH; Wooten GF; Watts RL; Guttman M; Racette BA; Perlmutter JS; Ahmed A; Shill HA; Singer C; Goldwurm S; Pezzoli G; Zini M; Saint-Hilaire MH; Hendricks AE; Williamson S; Nagle MW; Wilk JB; Massood T; Huskey KW; Laramie JM; DeStefano AL; Baker KB; Itin I; Litvan I; Nicholson G; Corbett A; Nance M; Drasby E; Isaacson S; Burn DJ; Chinnery PF; Pramstaller PP; Al-hinti J; Moller AT; Ostergaard K; Sherman SJ; Roxburgh R; Snow B; Slevin JT; Cambi F; Gusella JF; Myers RH
    BMC Med; 2008 Nov; 6():32. PubMed ID: 18986508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. G2019S LRRK2 mutation in familial and sporadic Parkinson's disease in Russia.
    Pchelina SN; Yakimovskii AF; Ivanova ON; Emelianov AK; Zakharchuk AH; Schwarzman AL
    Mov Disord; 2006 Dec; 21(12):2234-6. PubMed ID: 17044089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families.
    Ishihara L; Gibson RA; Warren L; Amouri R; Lyons K; Wielinski C; Hunter C; Swartz JE; Elango R; Akkari PA; Leppert D; Surh L; Reeves KH; Thomas S; Ragone L; Hattori N; Pahwa R; Jankovic J; Nance M; Freeman A; Gouider-Khouja N; Kefi M; Zouari M; Ben Sassi S; Ben Yahmed S; El Euch-Fayeche G; Middleton L; Burn DJ; Watts RL; Hentati F
    Mov Disord; 2007 Jan; 22(1):55-61. PubMed ID: 17115391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients.
    Floris G; Cannas A; Solla P; Murru MR; Tranquilli S; Corongiu D; Rolesu M; Cuccu S; Sardu C; Marrosu F; Marrosu MG
    Parkinsonism Relat Disord; 2009 May; 15(4):277-80. PubMed ID: 18805725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in LRRK2 other than G2019S are rare in a north American-based sample of familial Parkinson's disease.
    Pankratz N; Pauciulo MW; Elsaesser VE; Marek DK; Halter CA; Rudolph A; Shults CW; Foroud T; Nichols WC;
    Mov Disord; 2006 Dec; 21(12):2257-60. PubMed ID: 17078063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
    Yahalom G; Kaplan N; Vituri A; Cohen OS; Inzelberg R; Kozlova E; Korczyn AD; Rosset S; Friedman E; Hassin-Baer S
    Parkinsonism Relat Disord; 2012 Nov; 18(9):1039-41. PubMed ID: 22703868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The G2019S LRRK2 mutation: another morbid burden for Ashkenazi Jews may provide new insights on sporadic Parkinson's disease.
    Melamed E
    Mov Disord; 2013 Dec; 28(14):1912-4. PubMed ID: 24307480
    [No Abstract]   [Full Text] [Related]  

  • 14. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance.
    Gaig C; Ezquerra M; Marti MJ; Muñoz E; Valldeoriola F; Tolosa E
    Arch Neurol; 2006 Mar; 63(3):377-82. PubMed ID: 16533964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of the LRRK2 G2019S mutation in a UK community based idiopathic Parkinson's disease cohort.
    Williams-Gray CH; Goris A; Foltynie T; Brown J; Maranian M; Walton A; Compston DA; Sawcer SJ; Barker RA
    J Neurol Neurosurg Psychiatry; 2006 May; 77(5):665-7. PubMed ID: 16614029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of the LRRK2 G2019S mutation in siblings with Parkinson's disease.
    Lesage S; Leclere L; Lohmann E; Borg M; Ruberg M; Dürr A; Brice A;
    Neurodegener Dis; 2007; 4(2-3):195-8. PubMed ID: 17596714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.
    Healy DG; Falchi M; O'Sullivan SS; Bonifati V; Durr A; Bressman S; Brice A; Aasly J; Zabetian CP; Goldwurm S; Ferreira JJ; Tolosa E; Kay DM; Klein C; Williams DR; Marras C; Lang AE; Wszolek ZK; Berciano J; Schapira AH; Lynch T; Bhatia KP; Gasser T; Lees AJ; Wood NW;
    Lancet Neurol; 2008 Jul; 7(7):583-90. PubMed ID: 18539534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. G2019S LRRK2 mutation in French and North African families with Parkinson's disease.
    Lesage S; Ibanez P; Lohmann E; Pollak P; Tison F; Tazir M; Leutenegger AL; Guimaraes J; Bonnet AM; Agid Y; Dürr A; Brice A;
    Ann Neurol; 2005 Nov; 58(5):784-7. PubMed ID: 16240353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations.
    Ishihara L; Warren L; Gibson R; Amouri R; Lesage S; Dürr A; Tazir M; Wszolek ZK; Uitti RJ; Nichols WC; Griffith A; Hattori N; Leppert D; Watts R; Zabetian CP; Foroud TM; Farrer MJ; Brice A; Middleton L; Hentati F
    Arch Neurol; 2006 Sep; 63(9):1250-4. PubMed ID: 16966502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LRRK2 G2019S founder haplotype in the Chinese population.
    Tan EK; Skipper L; Tan L; Liu JJ
    Mov Disord; 2007 Jan; 22(1):105-7. PubMed ID: 17083102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.